Key Points
- CEO John Kao sold 298,000 shares of Alignment Healthcare on May 11 at an average price of $16.89, totaling about $5.03 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Despite the insider sale, the company’s latest quarterly results were solid: Alignment Healthcare posted EPS of $0.05, beating estimates by $0.04, and revenue of $1.24 billion, up 33.3% year over year.
- Wall Street remains broadly positive on ALHC, with a Moderate Buy consensus and an average price target of $24.60. Institutional ownership is also high, with hedge funds and institutions holding about 86.19% of the stock.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John Kao sold 298,000 shares of the company's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $16.89, for a total value of $5,033,220.00. Following the completion of the sale, the chief executive officer owned 1,508,641 shares in the company, valued at $25,480,946.49. This trade represents a 16.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alignment Healthcare Trading Down 0.6%
NASDAQ ALHC opened at $18.27 on Thursday. The business's 50-day moving average price is $19.12 and its two-hundred day moving average price is $19.49. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The firm has a market capitalization of $3.78 billion, a PE ratio of 203.00, a price-to-earnings-growth ratio of 2.57 and a beta of 1.26. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the previous year, the company posted ($0.05) EPS. The business's revenue was up 33.3% on a year-over-year basis. On average, analysts expect that Alignment Healthcare, Inc. will post 0.19 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Teacher Retirement System of Texas boosted its holdings in Alignment Healthcare by 85.8% during the third quarter. Teacher Retirement System of Texas now owns 102,827 shares of the company's stock worth $1,794,000 after purchasing an additional 47,472 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Alignment Healthcare during the third quarter worth about $3,499,000. Hudson Bay Capital Management LP purchased a new position in Alignment Healthcare during the third quarter worth about $4,581,000. Cinctive Capital Management LP purchased a new position in Alignment Healthcare during the third quarter worth about $3,814,000. Finally, Vanguard Group Inc. boosted its holdings in Alignment Healthcare by 5.0% during the third quarter. Vanguard Group Inc. now owns 13,968,584 shares of the company's stock worth $243,752,000 after purchasing an additional 664,769 shares during the last quarter. 86.19% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have commented on ALHC. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a research report on Friday, January 30th. Weiss Ratings raised shares of Alignment Healthcare from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday, May 7th. KeyCorp reissued an "overweight" rating and set a $28.00 target price on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Alignment Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.60.
Get Our Latest Stock Analysis on ALHC
Alignment Healthcare Company Profile
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
